Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 2/20 | 0.62 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.62 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29195353 | 0.90 | NR1H3 (0.55) | NR1H3NR1H2UTS2RKMT2ACASP3 | |
| SCHEMBL10926180 | 0.88 | CASP3 (0.56) | UTS2RKMT2ACASP3RXFP1HTT | |
| SCHEMBL2030026 | 0.87 | ALDH1A1 (0.55) | UTS2RKMT2ACASP3ALDH1A1RXFP1 | |
| SCHEMBL3024201 | 0.87 | CASP3 (0.58) | UTS2RKMT2ACASP3ALDH1A1RXFP1 | |
| SCHEMBL6336921 | 0.87 | CASP3 (0.58) | KMT2ACASP3ALDH1A1LMNARXFP1 | |
| SCHEMBL18669081 | 0.87 | TDP1 (0.70) | UTS2RKMT2ACASP3ALDH1A1LMNA | |
| SCHEMBL7945209 | 0.87 | CASP3 (0.55) | UTS2RKMT2ACASP3LMNARXFP1 | |
| SCHEMBL6777806 | 0.87 | RXFP1 (0.60) | KMT2ACASP3LMNARXFP1HTT | |
| SCHEMBL21503296 | 0.86 | UTS2R (0.49) | NR1H3NR1H2UTS2RKMT2ACASP3 | |
| SCHEMBL2564990 | 0.85 | CASP3 (0.53) | UTS2RKMT2ACASP3RXFP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| US-7390870-B2 | Immune-enhancing peptides | POSCO (KR) | 2008-06-24 | — | — | US | disclosed |
| US-7329761-B2 | Substituted imides | CELGENE CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| EP-0800514-B1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050090516-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2005-04-28 | — | — | US | disclosed |
| US-6844359-B2 | Substituted imides | CELGENE CORPORATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030055001-A1 | Immune-enhancing peptides | POSCO (KR) | 2003-03-20 | — | — | US | disclosed |
| US-20020143027-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2002-10-03 | — | — | US | disclosed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | disclosed |
| WO-1996020926-A9 | SUBSTITUTED IMIDES AS TNF INHIBITORS | — | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143027-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | NR1H3 4579/4885NR1H2 4447/4885UTS2R 3402/4885 |
| US-20050090516-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | NR1H3 4601/4885NR1H2 4462/4885UTS2R 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.